SpringWorks Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating ...

Halozyme Therapeutics stock is trading -17.97% below its average target price of $64.12 after marking a 2.8% during today's morning session. Analysts are giving the Mid-Cap Biotechnology company an ...

Halozyme (NASDAQ:HALO) has raised its financial guidance estimates for 2025 based on expected strong sales of products ...

Halozyme Therapeutics (HALO) reiterated full year 2024 financial guidance and increased full year 2025 and multi-year financial ...

EST Halozyme (HALO) announces new $250M accelerated share repurchase plan Stay Ahead of the Market:Discover outperforming stocks and ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today provided a financial update, reiterating full ...

January 05, 2025, 00:04 am ET, BY Joseph H.- Contributor| Editor: Thomas H. Kee Jr. ( Follow on LinkedIn) ...

Halozyme provides subcutaneous drug delivery solutions, with several major new products recently approved. Click here to find ...

FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.

Regulators squeezed in two final approvals before the calendar change with the UK approval of Merck’s Winrevair and the FDA’s ...

Halozyme's attempt to acquire Evotec was a bold move to diversify revenue, but was ultimately unsuccessful, impacting HALO's ...

In a significant advancement for cancer care, the U.S. Food and Drug Administration (FDA) has approved an injectable version ...